New radiation schedule tested to improve esophageal cancer treatment
NCT ID NCT06912074
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a shorter, more intense course of radiation (hypofractionated) is safer and more effective than the standard longer course for people with advanced esophageal cancer that cannot be surgically removed. All participants first receive two cycles of chemo-immunotherapy (albumin-bound paclitaxel, cisplatin, and toripalimab). Then they are randomly assigned to one of the two radiation schedules, both given with chemotherapy. The study will track cancer progression, survival, and side effects over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- albumin-bound paclitaxel, cisplatin, toripalimab, and radiation therapy
- What this could lead to
- If successful, this could identify a more effective radiation schedule that improves cancer control and reduces side effects for people with advanced esophageal cancer.
- What could go wrong
- This is an early phase 2 trial with only 134 participants, so results may not apply to everyone. The treatments have significant side effects, and the new schedule may not be better than the standard one.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an AI eye guide surgeons to safer, faster cancer removal?
- Can a triple punch of immunotherapy and chemoradiation wipe out esophageal tumors before surgery?
- Can early tumor response guide smarter cancer treatment?
- Could a smart combo of drugs and radiation help some esophageal cancer patients skip surgery?
- Could more surgery and radiation after immunotherapy keep esophageal cancer at bay?
- Blood and tissue markers could forecast esophageal cancer return